One of the most interesting results here seems to be that the vaccine benefits from a long period between the doses, with the efficacy rising to 76% three months after the first dose, then to 82% after the 2nd dose. This seems to imply the approach of vaccinating as many people as possible with one dose of this vaccine and leaving a long gap to the 2nd one is the right one, as used in the UK.